Venous Thrombosis in Children With Solid Tumors

Schiavetti, Amalia; Foco, Micaela; Ingrosso, Annapaola; Bonci, Enea; Conti, Laura; Matrunola, M

doi:10.1097/mph.0b013e31815f88b7

Cited by 21 publications

(22 citation statements)

References 22 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of asymptomatic CVC‐related VTE in our cohort was also lower compared to previous studies investigating asymptomatic CVC‐related VTE (Table ) . Two studies investigated asymptomatic CVC‐related VTE in patients who had their CVC removed .…”

Section: Discussioncontrasting

confidence: 61%

Prevalence of Symptomatic and Asymptomatic Thrombosis in Pediatric Oncology Patients With Tunneled Central Venous Catheters

Schoot

Wetering

Stijnen

et al. 2016

Pediatr Blood Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 61%

Prevalence of Symptomatic and Asymptomatic Thrombosis in Pediatric Oncology Patients With Tunneled Central Venous Catheters

Schoot

Wetering

Stijnen

et al. 2016

Pediatr Blood Cancer

View full text Add to dashboard Cite

show abstract

“…A total of 35 publications were identified from the search strategies [1,2,; eight were excluded from the analysis [5][6][7][8][9][10][11][12] because of lack of information on outcome for individual cases. One of the excluded articles investigated the association of hereditary prothrombotic disorders with all types of intracardiac thrombus [6].…”

Section: Resultsmentioning

confidence: 99%

“…In the Fontan procedure, with the RA connected to the pulmonary artery bypassing the right ventricle, the velocity of blood flow to the pulmonary circulation is decreased compared with that in a normal heart. Prematurity, malignancies, protein losing state (nephrotic syndrome, renal failure, and gut failure), and parenteral nutrition are known to be associated with hypercoagulable states and are additive risk factors for RAT in the presence of central venous catheters [7,42,43].…”

Section: Discussionmentioning

confidence: 99%

Neonatal and childhood right atrial thrombosis: recognition and a risk-stratified treatment approach

Yang

Williams

Brandão

et al. 2010

Blood Coagulation & Fibrinolysis

View full text Add to dashboard Cite

Pediatric literature and guidelines of treatment options for right atrial thrombosis (RAT) are lacking; thus, this review summarizes the available literature on RAT in infants and children. Medline search identified 35 publications, with 27 prospective or retrospective case series included for data analysis. A total of 122 cases of RAT were identified. The mean age of patients is 3.58 years (n = 86) with a strong predominance in the neonatal and infancy period. Ninety-one percent of cases were found to be associated with central venous catheters, 40.8% are premature neonates, 27.2% are postcardiac surgery patients, and 19.2% have underlying malignancies. Gut failure with total parenteral nutrition given via the central venous catheters occurred in 45.6% of patients. The most frequent presenting symptoms are respiratory distress and arrhythmia, and 56.8% (42 of 74) were asymptomatic. Our study defined high-risk features on echocardiogram as large size, more than 2 cm in any dimension, pedunculated, mobile, or snake-shaped, and mobile. Our result confirmed there is significant difference in the mortality for the high-risk group (16.7%; three of 18) versus the low risk group (0%; n = 32; P = 0.0416). Moreover, none of the asymptomatic patients showed progression in disease or died. Asymptomatic and hemodynamically stable patients with RAT who are at low risk are associated with good prognosis irrespective of treatment. We recommended removal of central venous line if possible, with or without anticoagulation for this group of patients. Systemic anticoagulation therapy should be given to all high-risk or symptomatic RAT patients. Surgical thrombectomy or thrombolytic therapy carries significant risk and should be considered individually.

show abstract

“…The prevalence of deep vein thrombosis (DVT) in cancer patients is up to six-fold higher than in the general population [1][2][3]. Cancer patients are also more susceptible to recurrent venous thromboembolism (VTE) [4][5][6][7][8], and this risk is particularly high in patients with pancreatic cancer [9][10][11]. VTE events contribute greatly to morbidity and mortality, and also challenge physicians by delaying, interrupting or interfering with cancer therapy [12].…”

Section: Introductionmentioning

confidence: 99%

Tissue factor expressed by circulating cancer cell‐derived microparticles drastically increases the incidence of deep vein thrombosis in mice

Thomas

Brill

Mezouar

et al. 2015

Journal of Thrombosis and Haemostasis

125

122

View full text Add to dashboard Cite

Background The risk of thrombotic complications such as deep vein thrombosis (DVT) during tumor development is well known. Tumors release into circulation procoagulant microparticles (MPs) that can participate in thrombus formation following vessel injury. The importance of this MP tissue factor (TF) in the initiation of cancer-associated DVT remains uncertain. Objective To address how pancreatic cancer MPs promote DVT in vivo. Methods We combined a DVT mouse model where thrombosis is induced by flow restriction of the inferior vena cava with one of subcutaneous pancreatic cancer in C57BL/6J mice. We infused high and low TF tumor MPs to determine the importance of TF in experimental cancer-associated DVT. Results Both tumor-bearing mice and mice infused with tumor MPs submitted to 3 hours of partial flow restriction developed an occlusive thrombus; fewer than a third of the control mice did. We observed that MPs adhered to neutrophil extracellular traps (NETs), functionally important players during DVT, whereas neither P-selectin nor GPIb were required for the MP recruitment in DVT. The thrombotic phenotype induced by MP infusion was suppressed by hirudin suggesting the importance of thrombin generation. TF carried by tumor MPs was essential to promote DVT as mice infused with low TF tumor MPs had less thrombosis than mice infused with high TF tumor MPs. Conclusions TF expressed on tumor MPs contributes to the increased incidence of cancer-associated venous thrombosis in mice in vivo. These MPs may adhere to NETs formed at the site of thrombosis.

show abstract

Venous Thrombosis in Children With Solid Tumors

Cited by 21 publications

References 22 publications

Prevalence of Symptomatic and Asymptomatic Thrombosis in Pediatric Oncology Patients With Tunneled Central Venous Catheters

Prevalence of Symptomatic and Asymptomatic Thrombosis in Pediatric Oncology Patients With Tunneled Central Venous Catheters

Neonatal and childhood right atrial thrombosis: recognition and a risk-stratified treatment approach

Tissue factor expressed by circulating cancer cell‐derived microparticles drastically increases the incidence of deep vein thrombosis in mice

Contact Info

Product

Resources

About